Advertisement
New Zealand markets closed
  • NZX 50

    12,105.29
    +94.63 (+0.79%)
     
  • NZD/USD

    0.5981
    -0.0025 (-0.42%)
     
  • NZD/EUR

    0.5535
    -0.0007 (-0.13%)
     
  • ALL ORDS

    8,153.70
    +80.10 (+0.99%)
     
  • ASX 200

    7,896.90
    +77.30 (+0.99%)
     
  • OIL

    82.57
    +1.22 (+1.50%)
     
  • GOLD

    2,233.60
    +20.90 (+0.94%)
     
  • NASDAQ

    18,277.99
    -2.85 (-0.02%)
     
  • FTSE

    7,973.15
    +41.17 (+0.52%)
     
  • Dow Jones

    39,750.07
    -10.01 (-0.03%)
     
  • DAX

    18,510.59
    +33.50 (+0.18%)
     
  • Hang Seng

    16,541.42
    +148.58 (+0.91%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • NZD/JPY

    90.3770
    -0.4030 (-0.44%)
     

The Zacks Analyst Blog Highlights: Johnson & Johnson, Apple, Goldman Sachs, IBM and Netflix

For Immediate Release

Chicago, IL – May 21, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Johnson & Johnson JNJ, Apple Inc. AAPL, The Goldman Sachs Group, Inc. GS, IBM Corp. IBM and Netflix, Inc. NFLX.

Here are highlights from Monday’s Analyst Blog:

Top Analyst Reports for Johnson & Johnson, Apple and Goldman Sachs

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson, Apple Inc. and The Goldman Sachs Group, Inc.. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

ADVERTISEMENT

You can see all of today’s research reports here >>>

Johnson & Johnson’s shares have outperformed the Zacks Large Cap Pharmaceuticals industry so far this year (+7.4% vs. -1.1%). J&J’s sales and earnings growth is expected to accelerate in the long run, supported by contribution from new drugs like Tremfya and successful label expansion of cancer drugs like Imbruvica and Darzalex and immunology drug, Stelara.

J&J is also making rapid progress with its pipeline and line extensions. It has already gained FDA approval for two new drugs in 2019, Balversa and Spravato. Meanwhile, share buybacks and restructuring initiatives should provide bottom-line support. However, headwinds like biosimilar/generic competition and pricing pressure remain.

Shares of Apple have outperformed the broader S&P 500 index on a year-to-date basis (+19.8% vs. +13.4%). Apple’s services segment, in particular, is expected to grow strongly on solid App Store sales and increasing adoption of Apple Music and Apple Pay.

But there are significant headwinds for Apple. Weak iPhone demand, particularly in China and emerging economies, is a headwind. Further, the company continues to lose share in the smartphone market due to stiff competition from Chinese handset makers. Moreover, the ongoing U.S.-China trade war doesn’t bode well for the company.

Goldman Sachs'shares have outperformed the Zacks Financial - Investment Bank industry so far this year, gaining +18.1% vs +7.8%. Goldman’s first-quarter 2019 results reflected solid financial advisory revenues and lower expenses, partly offset by disappointing performance of Institutional Client Services unit and lower underwriting business. Notably, Goldman has been embroiled in the scandal related to the multibillion-dollar 1Malaysia Development Bhd (1MDB), which is a major concern.

Nevertheless, Goldman’s well-diversified business and focus to capitalize on growth opportunities through strategic moves, along with cost-control efforts, will continue to strengthen the overall business.

Other noteworthy reports we are featuring today include IBM Corp. and Netflix, Inc..

Zacks' Top 10 Stocks for 2019

In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?

Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.

See Latest Stocks Today >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com                    

https://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
International Business Machines Corporation (IBM) : Free Stock Analysis Report
 
Netflix, Inc. (NFLX) : Free Stock Analysis Report
 
Johnson & Johnson (JNJ) : Free Stock Analysis Report
 
Apple Inc. (AAPL) : Free Stock Analysis Report
 
The Goldman Sachs Group, Inc. (GS) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.